Moreover, a significant functional recovery, decreased Aβ burden, as well as a rebalance of immune/inflammatory response overshoot and reduced tissue damage, have been shown in a transgenic mouse model of AD subjected to anti-TRAIL treatment [10,12]. The gene discussed is TNFSF10; the disease is Alzheimer disease.